APM
BPMC

Avidity Partners Management’s Blueprint Medicines BPMC Stock Holding History

Avidity Partners Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,500
Closed -$6.06M – 62
2025
Q1 		$6.06M Sell
68,500
-108,100
-61% -$10.5M 1.16% 35
2024
Q4 		$15.4M Sell
176,600
-138,400
-44% -$12.7M 1.51% 28
2024
Q3 		$29.1M Sell
315,000
-68,000
-18% -$6.75M 1.49% 27
2024
Q2 		$41.3M Sell
383,000
-43,000
-10% -$4.3M 1.75% 19
2024
Q1 		$40.4M Sell
426,000
-189,000
-31% -$16.2M 1.3% 29
2023
Q4 		$56.7M Sell
615,000
-136,600
-18% -$8.85M 2.07% 16
2023
Q3 		$37.7M Buy
751,600
+336,600
+81% +$18M 1.52% 30
2023
Q2 		$26.2M Buy
+415,000
New +$22.6M 0.92% 46
2022
Q2 		– Sell
-291,184
Closed -$18.6M – 87
2022
Q1 		$18.6M Sell
291,184
-703,816
-71% -$50.5M 0.39% 55
2021
Q4 		$107M Buy
995,000
+163,000
+20% +$17.1M 2.26% 16
2021
Q3 		$85.5M Buy
832,000
+268,800
+48% +$25M 1.9% 14
2021
Q2 		$49.5M Buy
563,200
+17,200
+3% +$1.58M 1.34% 27
2021
Q1 		$53.1M Buy
546,000
+306,000
+128% +$30.6M 1.47% 24
2020
Q4 		$26.9M Buy
+240,000
New +$25.3M 0.87% 43

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Avidity Partners Management's BPMC Position: Q2 2025 in Review

Avidity Partners Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 68,500 shares — an estimated $6.06M sold.

Avidity Partners Management first reported a position in BPMC in Q4 2020 and held it in 14 quarters. The position peaked at $107M in Q4 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Avidity Partners Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 68,500 Blueprint Medicines shares in Q2 2025, an estimated $6.06M.
  • Avidity Partners Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 14 quarters.
  • Avidity Partners Management's Blueprint Medicines position peaked at $107M in Q4 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.